Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 2, 1996, Pages 658-666

  Ring, Barbara J ^a   Catlow, John ^a   Lindsay, Thomas J ^a   Gillespie, Todd ^a   Roskos, Lorin K ^a   Cerimele, Benito J ^a   Swanson, Steven P ^a   Hamman, Mitchell A ^b   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DRUG DERIVATIVE; MIXED FUNCTION OXIDASE; NEUROLEPTIC AGENT; OLANZAPINE; OXIDOREDUCTASE; PIRENZEPINE;

ARTICLE; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; OXIDOREDUCTASES; PIRENZEPINE;

EID: 0030077735     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. BERTHOU, F., RATANASAVANH, D., RICHE, C., PICART, D. J., VOIRIN, T. AND GUILLOUZO, A.: Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica 19: 401-417, 1989.
2. BERTILSSON, L., CARRILLO, J. A., DAHL, M. L., LLERENA, A , ALM, C., BONDESSON, U., LINDSTROM, L., DE LA RUBIA, I R., RAMOS, S. AND BENITEZ, J.: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38: 471-473, 1994.
3. BOXENBAUM, H G., RIEGELMAN, S. AND ELASHOFF, R. M.: Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm. 2: 123-148, 1974.
4. BROSEN, K., SKJELBO, E., RASMUSSEN, B. B., POULSEN, H. E. AND LOFT, S., Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45: 1211-1214, 1993.
5. BUTLER, M. A., IWASAKI, M., GUENGERICH, F. P. AND KADLUBAR, F. F.: Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci USA 86: 7696-7700, 1989.
6. CAMPBELL, M. E., GRANT, K. M , INABA, T. AND KALOW, W.; Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible eytochrome(s) P-450 in human liver microsomes. Drug Metab. Disp 15: 237-248, 1987.
7. CASHMAN, J. R., PARK, S. B., YANG, Z.-C , WASHINGTON, C. B., GOMEZ, D Y., GIACOMINI, K. M. AND BRETT, C M.: Chemical, enzymatic and human enantioselective S-oxygenation of cimetidine. Drug Metab. Dispos. 21: 587-597, 1993.
8. CASHMAN, J. R., PARK, S. B., YANG, Z.-C., WRIGHTON, S. A., JACOB, P. AND BENOWITZ, N. L.: Metabolism of nicotine by human liver microsomes: Stereo-selective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol. 5: 639-646, 1992.
9. CONNEY, A. H., PANTUCK, E. J., HSIAO, K.-C., GARLAND, W. A., ANDERSON, K. E., ALVARES, A. P. AND KAPPAS, A.: Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin. Pharmacol. Ther. 20:633-642, 1976.
10. DAHL, M. L., LLERENA, A., BONDESSON, U., LINDSTROM, L. AND BERTILSSON, L.: Disposition of clozapine in man: Lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin. Pharmacol. 37: 71-74, 1994.
11. DIAZ, D., FABRE, I., DAUJAT, M., AUBERT, B. S., BORIES, P., MICHEL, H. AND MAUREL, P.: Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99: 737-747, 1990.
12. FISHER, V., VOGELS, B., MAURER, G. AND TYNES, R. E.: The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 260: 1355-1360, 1992.
13. FUHR, W., WOLFF, T., HARDER, S., SCHYMANSKI, P. AND STAIB, A. H.: Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab. Disp. 18: 1005-1010, 1990.
14. HALL, S. D. HAMMAN, M. A., RETTIE, A. E., WIENKERS L. C., TRAGER, W. F., VANDENBRANDEN, M. AND WRIGHTON, S. A.: Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab. Dispos. 22: 975-978, 1994.
15. HOUSTON, J. B.: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 27: 1469-1479, 1994.
16. JERLING, M., LINDSTROM, L., BONDESSON, U. AND BERTILSSON, L.: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther. Drug Monitor. 16: 368-374, 1994.
17. KALOW, W. AND TANG, B.-K.: Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther. 49: 44-48, 1991.
18. 14C]olanzapine, a new antipsychotic agent, in humans (Abstract). ISSX Proc. 6: 100, 1994.
19. LEMOINE, A., GAUTIER, J. C., AZOULAY, K., KIFFEL, L., BELLOC, C., GUENGERICH, F. P., MAUREL, P., BEAUNE, P. M. AND LEROUX, J. P.: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43: 827-832, 1993.
20. LLEDO, P.: Variations in drug metabolism due to genetic polymorphism. Drug. Invest. 5: 19-34, 1993.
21. LLERENA, A., HERRIAZ, A. G., COBALEDA, J., JOHANSSON, I. AND DAHL, M. L.: Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther. 54: 606-611, 1993.
22. LOI, C.-M., PARKER, B. M., CUSACK, B J. AND VESTAL, R. E.: Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br. J. Clin Pharmacol. 36: 195-200, 1993.
23. +-Glucuronidation of aliphatic tertiary-amines in human-antidepressant versus antipsychotic drugs. Xenobiotica 25: 291-301, 1995.
24. +-glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biol. Mass Spec. 23: 147-148 (1994).
25. MANI, C., HODGSON, E. AND KUPFER, D.: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos. 21: 657-661, 1993.
26. MOORE, N. A., CALLIGARO, D. O., WONG, D. T., BYMASTER, F. AND TYE, N. C.: The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs. 2: 281-293, 1993.
27. NAKAMURA, K., GOTO, F., RAY, W. A., MCALLISTER, C. B. AND JACQZ, E.: Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38: 402-408, 1985.
28. PECK, C. C., TEMPLE, E. AND COLLINS, J. M.: Understanding consequences of concurrent therapies. J. A. M. A. 269: 1550-1552, 1993.
29. PIRMOHAMED, M., WILLIAMS, D., MADDEN, S., TEMPLETON, E. AND PARK, B. K.: Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272: 984-990, 1995.
30. RELLING, M. V., LIN, J.-S., AYERS, G. D. AND EVANS, W. E.: Racial and gender differences in N-acetyltransferase, xanthine oxidase and CYP1A2 activities. Clin. Pharmacol. Ther. 52: 643-658, 1992.
31. Ring , B. J., Binkley, S. N., Vandenbranden, M. and Wrighton, S. A.: In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br. J. Clin. Pharmacol., in press.
32. SEGEL, I. H.: Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley and Sons, New York, NY, 1975.
33. TUCKER, G. T.: The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Int. J. Clin Pharmacol. Ther. Toxicol. 30: 550-553, 1992.
34. VAN DER HOEVEN, T. A. AND COON, M. J.: Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249: 6302-6310, 1974.
35. WHIGHTON, S. A. AND STEVENS, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21, 1992.
36. WRIGHTON, S. A., STEVENS, J. C., BECKER G. W. AND VANDENBRANDEN, M.: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306: 240-245, 1993a.
37. WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J., SHIPLEY, L. A. AND RING, B. J.: In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab. Rev. 25: 453-484, 1993b.
38. ZIEGLER, D. M.: Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 33: 179-199, 1993.